Prof. Atul Deodhar (Oregon Health & Science University, Portland, OR, USA) kindly took the time to discuss the 3-yr interim health-related quality of life (HRQoL) data from the phase 2b BE AGILE study (NCT02963506) and its open-label extension (NCT03355573) investigating bimekizumab in ankylosing spondylitis.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The abstract entitled ‘Bimekizumab Shows Sustained and Meaningful Long-Term Improvements in Health-Related Quality of Life in Ankylosing Spondylitis: Interim Results After 3 Years of Treatment in an Ongoing Phase 2b Study’ (ABSTRACT NUMBER: 0922) was presented at the ACR Convergence, 5-9 November 2021.
- Could you tell us a little about bimekizumab and its mechanism of action? (0:14)
- What have previous phase 2 studies with bimekizumab demonstrated and what were the aims of the current analysis? (0:48)
- Could you tell us about the design of the current analysis and the overall findings? (1:33)
Disclosures: Prof. Atul Deodhar has been a consultant/ advisory board member for AbbVie, Amgen, Aurinia, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Glaxo Smith & Kline, Janssen, Moonlake, Novartis, Pfizer and UCB, and received research grants from AbbVie, Eli Lilly, Glaxo Smith & Kline, Novartis, Pfizer and UCB.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Gina Furnival.
Filmed in coverage of virtual ACR Convergence 2021.
Share this Video
Related Videos In Rheumatic Diseases
Patrick Durez, ACR 2022: Factors associated with disease flare following COVID vaccination in inflammatory rheumatic and musculoskeletal diseases
The EULAR Coronavirus Vaccine (COVAX) physician-reported registry registered patients with pre-existing rheumatic and musculoskeletal diseases, who have been vaccinated against COVID-19. touchIMMUNOLOGY were delighted to speak with Prof Patrick Durez (Cliniques Universitaires Saint-Luc – Université Catholique de Louvain (UCL), Brussels, Belgium) to discuss the aims, methodology and findings of this study looking at factors associated […]
Robert Spiera, ACR 2022: Sarilumab for glucocorticoid resistant polymyalgia rheumatica – the SAPHYR study
The SAPHYR study (NCT03600818) investigated sarilumab, a fully human anti–IL-6Rα monoclonal antibody, in patients with glucocorticoid resistant polymyalgia rheumatica (PMR), measuring efficacy by sustained remission in PMR. touchIMMUNOLOGY were delighted to speak with Dr. Robert Spiera (Weill Cornell Medical College, New York, NY, USA) around the aims, design, inclusion criteria and findings from the SAPHYR […]
Catherine Sims, ACR 2022: Azathioprine metabolite levels throughout pregnancy in women with rheumatic disease
Women with rheumatic disease, such as systemic lupus erythematosus, are often prescribed azathioprine to control disease activity during pregnancy. However, the changes in azathioprine metabolite levels throughout pregnancy in such women are yet to be well-characterized. It was a pleasure to talk with Dr. Catherine Sims (Duke University, Durham, NC, USA) around her study investigating […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!